BR9904283A - Complexos estáveis de compostos fracamente solúveis - Google Patents

Complexos estáveis de compostos fracamente solúveis

Info

Publication number
BR9904283A
BR9904283A BR9904283-5A BR9904283A BR9904283A BR 9904283 A BR9904283 A BR 9904283A BR 9904283 A BR9904283 A BR 9904283A BR 9904283 A BR9904283 A BR 9904283A
Authority
BR
Brazil
Prior art keywords
soluble compounds
poorly soluble
complexes
ionic polymers
insoluble
Prior art date
Application number
BR9904283-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Antonio A Albano
Wantanee Phuapradit
Harpreet K Sandhu
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9904283(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9904283A publication Critical patent/BR9904283A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR9904283-5A 1998-09-22 1999-09-21 Complexos estáveis de compostos fracamente solúveis BR9904283A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10133698P 1998-09-22 1998-09-22
US13653199P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
BR9904283A true BR9904283A (pt) 2000-09-26

Family

ID=26798138

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9904283-5A BR9904283A (pt) 1998-09-22 1999-09-21 Complexos estáveis de compostos fracamente solúveis

Country Status (32)

Country Link
US (1) US6350786B1 (enExample)
EP (1) EP0988863B2 (enExample)
JP (5) JP2000095708A (enExample)
KR (1) KR100362019B1 (enExample)
CN (1) CN1201821C (enExample)
AR (2) AR022096A1 (enExample)
AT (1) ATE265232T1 (enExample)
AU (1) AU770745B2 (enExample)
BR (1) BR9904283A (enExample)
CA (1) CA2282906C (enExample)
CO (1) CO5140077A1 (enExample)
CZ (1) CZ300215B6 (enExample)
DE (1) DE69916733T3 (enExample)
DK (1) DK0988863T4 (enExample)
ES (1) ES2218918T5 (enExample)
HR (1) HRP990287B1 (enExample)
HU (1) HU228341B1 (enExample)
ID (1) ID24034A (enExample)
IL (1) IL131957A (enExample)
MA (1) MA26692A1 (enExample)
MY (1) MY124377A (enExample)
NO (1) NO326928B1 (enExample)
NZ (1) NZ337884A (enExample)
PE (1) PE20001049A1 (enExample)
PL (1) PL202757B1 (enExample)
PT (1) PT988863E (enExample)
RS (1) RS50193B (enExample)
RU (1) RU2240827C2 (enExample)
SG (1) SG97131A1 (enExample)
SI (1) SI0988863T2 (enExample)
TR (1) TR199902324A3 (enExample)
TW (1) TWI234465B (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
US6440959B1 (en) 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
PE20010659A1 (es) * 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
JP4786113B2 (ja) * 2000-05-16 2011-10-05 オーソーマクニール ファーマシューティカル， インコーポレイテッド 超臨界二酸化炭素を用いる医療用装置のコーティング方法
US6469179B1 (en) 2000-10-03 2002-10-22 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
AU2002310567B2 (en) * 2001-05-30 2005-10-20 Csir Method of encapsulating an active substance
US20030044514A1 (en) * 2001-06-13 2003-03-06 Richard Robert E. Using supercritical fluids to infuse therapeutic on a medical device
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
SK15732003A3 (sk) 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
IL162819A0 (en) * 2002-02-01 2005-11-20 Pfizer Prod Inc Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
ATE442130T1 (de) 2002-08-12 2009-09-15 Bend Res Inc Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
DE10351087A1 (de) * 2003-10-31 2005-05-25 Bayer Technology Services Gmbh Feste Wirkstoff-Formulierung
EP3216449A1 (en) * 2003-11-14 2017-09-13 EA Pharma Co., Ltd. Oral administration preparation of phenylalanine derivatives
CA2546115C (en) 2003-11-14 2013-01-08 Ajinomoto Co., Inc. Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives
RU2411043C2 (ru) * 2004-04-01 2011-02-10 Юниверсите Де Льеж Фармацевтические композиции пиримидин-2,4,6-трионов
AR049915A1 (es) * 2004-06-14 2006-09-13 Anacor Pharmaceuticals Inc Compuestos con contenido de boro y metodos de uso de los mismos
WO2006062980A2 (en) * 2004-12-07 2006-06-15 Nektar Therapeutics Stable non-crystalline formulation comprising tiagabine
CN101115469A (zh) * 2004-12-28 2008-01-30 卫材R&D管理有限公司 速崩片及其制造方法
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
RU2411045C2 (ru) * 2005-01-27 2011-02-10 Институт Нефтехимического Синтеза Имени А.В. Топчиева Ран Гидрофильные биологически совместимые адгезивные композиции и их применение
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
CA2608952A1 (en) * 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
BRPI0611863B1 (pt) * 2005-06-22 2021-11-23 Plexxikon, Inc Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
PE20080422A1 (es) * 2006-08-10 2008-04-28 Cipla Ltd Composicion solida antirretroviral de administracion oral
US20080107725A1 (en) * 2006-10-13 2008-05-08 Albano Antonio A Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
JPWO2008081829A1 (ja) * 2006-12-27 2010-04-30 アステラス製薬株式会社 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
EP1997479A1 (en) * 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
JP2010533729A (ja) 2007-07-17 2010-10-28 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物と方法、及びそのための適応
CA2702935A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
US7794750B2 (en) * 2008-06-20 2010-09-14 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US8632805B2 (en) * 2008-06-20 2014-01-21 Mutual Pharmaceutical Company, Inc. Controlled-release formulations, method of manufacture, and use thereof
US20100099696A1 (en) * 2008-10-16 2010-04-22 Anthony Edward Soscia Tamper resistant oral dosage forms containing an embolizing agent
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
DK2414356T3 (en) 2009-04-03 2015-12-14 Hoffmann La Roche PROPAN-1-sulfonic acid {3- [5- (4-CHLORO-PHENYL) -1H-pyrrolo [2,3-b] pyridine-3- carbonyl] -2,4-difluorophenyl) -AMIDSAMMENSÆTNINGER AND USES THEREOF
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011057022A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
KR20130126451A (ko) * 2010-05-31 2013-11-20 아스테라스 세이야쿠 가부시키가이샤 트라이아졸 화합물의 고체 분산체
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
RU2013139701A (ru) 2011-02-17 2015-03-27 Ф. Хоффманн-Ля Рош Аг Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
HUE030883T2 (en) 2011-06-20 2017-06-28 H Lundbeck As Deuterated 1-piperazino-3-phenylindanes for the treatment of schizophrenia
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
IN2014CN02290A (enExample) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
US9457093B2 (en) * 2011-10-14 2016-10-04 Array Biopharma Inc. Solid dispersions of a ERB2 (HER2) inhibitor
RU2018138976A (ru) * 2012-03-23 2018-12-06 Эррэй Биофарма Инк. Лечение рака головного мозга
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
CA2891502A1 (en) 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US10195150B2 (en) 2012-12-20 2019-02-05 Kashiv Pharma, Llc Orally disintegrating tablet formulation for enhanced bioavailability
EA028009B1 (ru) 2013-01-22 2017-09-29 Ф.Хоффманн-Ля Рош Аг Фармацевтическая композиция с улучшенной биодоступностью
TWI615157B (zh) 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
US20160213575A1 (en) * 2013-09-11 2016-07-28 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
CA2928772A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
WO2016193779A1 (en) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
ES3033634T3 (en) * 2016-12-13 2025-08-06 Transthera Sciences Nanjing Inc Multi-kinase inhibitor compound, and crystal form and use thereof
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
RU2725879C2 (ru) * 2018-07-26 2020-07-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
WO2020114853A1 (en) 2018-12-03 2020-06-11 H. Lundbeck A/S Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
WO2021150981A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
AU2021212258A1 (en) 2020-01-31 2022-09-29 Flex Pharma, Llc Amorphous nilotinib microparticles and uses thereof
JP7705715B2 (ja) 2020-03-03 2025-07-10 デクセリアルズ株式会社 画像表示装置の製造方法
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
HUT43575A (en) * 1985-11-27 1987-11-30 Syntex Inc Process for producing amorphous benzimidazol derivatives and pharmaceutical compositions containing them
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
JP2528706B2 (ja) † 1988-05-30 1996-08-28 ゼリア新薬工業株式会社 ジヒドロピリジン化合物の製剤組成物
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH0729926B2 (ja) † 1989-07-25 1995-04-05 大塚製薬株式会社 易吸収性製剤用組成物
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1992018106A1 (fr) † 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
TW493991B (en) 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
GB9511220D0 (en) † 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
PT784974E (pt) * 1995-07-26 2003-09-30 Kyowa Hakko Kogyo Kk Preparacao de derivados de xantina numa dispersao solida
AU7106996A (en) † 1995-09-07 1997-03-27 Fuisz Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19548624A1 (de) 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH09208459A (ja) * 1996-02-07 1997-08-12 Eisai Co Ltd 溶解性を改良した製剤
ATE314843T1 (de) 1996-03-12 2006-02-15 Pg Txl Co Lp Wasserlösliche paclitaxel-prodrogen
ES2224256T3 (es) * 1996-06-28 2005-03-01 Schering Corporation Disolucion solida de un agente antifungico con biodisponibilidad mejorada.
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
CZ299068B6 (cs) 1998-03-17 2008-04-16 F. Hoffmann-La Roche Ag Substituovaný bisindolylmaleinimid a farmaceutický prostredek s jeho obsahem

Also Published As

Publication number Publication date
NO994583D0 (no) 1999-09-21
NZ337884A (en) 2001-02-23
DE69916733T3 (de) 2009-09-24
KR20000023426A (ko) 2000-04-25
SI0988863T2 (sl) 2009-08-31
EP0988863A3 (en) 2000-08-09
HUP9903189A3 (en) 2009-07-28
DK0988863T4 (da) 2009-06-08
EP0988863A2 (en) 2000-03-29
CO5140077A1 (es) 2002-03-22
CZ330499A3 (cs) 2000-04-12
CN1251312A (zh) 2000-04-26
JP2013035875A (ja) 2013-02-21
NO994583L (no) 2000-03-23
AR022096A1 (es) 2002-09-04
HU228341B1 (en) 2013-03-28
JP6253135B2 (ja) 2017-12-27
AR080892A2 (es) 2012-05-16
ES2218918T3 (es) 2004-11-16
PL335592A1 (en) 2000-03-27
TR199902324A2 (xx) 2000-04-21
DK0988863T3 (da) 2004-08-30
CA2282906A1 (en) 2000-03-22
JP2000095708A (ja) 2000-04-04
PT988863E (pt) 2004-07-30
US6350786B1 (en) 2002-02-26
SI0988863T1 (en) 2004-08-31
AU4880799A (en) 2000-03-23
JP6534979B2 (ja) 2019-06-26
HU9903189D0 (en) 1999-11-29
ES2218918T5 (es) 2009-06-23
KR100362019B1 (ko) 2002-11-23
CN1201821C (zh) 2005-05-18
RU2240827C2 (ru) 2004-11-27
JP2007224048A (ja) 2007-09-06
HK1026632A1 (en) 2000-12-22
TWI234465B (en) 2005-06-21
SG97131A1 (en) 2003-07-18
CA2282906C (en) 2010-07-20
IL131957A (en) 2005-06-19
MY124377A (en) 2006-06-30
RS50193B (sr) 2009-05-06
HRP990287A2 (en) 2000-06-30
ID24034A (id) 2000-07-06
HUP9903189A2 (hu) 2000-06-28
TR199902324A3 (tr) 2000-04-21
PE20001049A1 (es) 2000-10-17
IL131957A0 (en) 2001-03-19
EP0988863B2 (en) 2009-03-18
ATE265232T1 (de) 2004-05-15
MA26692A1 (fr) 2004-12-20
JP2016196515A (ja) 2016-11-24
JP2015187170A (ja) 2015-10-29
AU770745B2 (en) 2004-03-04
DE69916733T2 (de) 2005-03-31
PL202757B1 (pl) 2009-07-31
EP0988863B1 (en) 2004-04-28
NO326928B1 (no) 2009-03-16
HRP990287B1 (en) 2004-12-31
CZ300215B6 (cs) 2009-03-18
DE69916733D1 (de) 2004-06-03
YU47399A (enExample) 2002-08-12

Similar Documents

Publication Publication Date Title
BR9904283A (pt) Complexos estáveis de compostos fracamente solúveis
BR9815159A (pt) Preparação de conjugados de polietileno glicol-grf especìfica ao sìtio
BR0110914A (pt) Composição farmacêutica lìquida, conjugado, processo para preparação e utilização de uma composição, processo para o tratamento e prevenção de enfermidades que envolvem anemia e dispositivo para liberação local e sistêmica sustentada de uma composicão
BR0007742A (pt) Conjugados iÈnicos moleculares de poliésteres biodegradáveis e polipeptìdeos bioativos
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
BR9911077A (pt) Polìmeros absorventes de água com moléculas de espaço oco supramoleculares, processos para a sua preparação e seu emprego
BR0014271A (pt) Composições antivirais
TR199900674T2 (xx) Kinazolin t�revleri ve bunlar� i�eren farmas�tik bile�imler.
DK1066044T3 (da) Dextranformuleringer til behandling af inflammatoriske ledsygdomme
FI924969A0 (fi) Latenta kedoeverfoeringsmedel av tiolmerkaptantyp och deras anvaendning vid syntes av polymerer
DE60207831D1 (de) Thiol-modifizierte hyaluronan-derivate
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
AR008378A1 (es) Conjudados de interferon
ATE195721T1 (de) Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen
ES2164218T3 (es) Derivados de camptotecina.
ATE287911T1 (de) Verwendung von poly(diallylamin) polymeren
MA20670A1 (fr) Compositions par la preparation par extrusion de microparticules permettant la liberation prolongee d'une substance biologiquement active et les microparticules ainsi obtenues
DE60212819D1 (de) Salzformarme polyallylamine
BR9901782A (pt) Forma para dosagem de nefazodona.
TR199802344A2 (xx) �kame edilmi� imidazolidin t�revleri
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
BR0011831A (pt) Compostos, processo para preparar os mesmos, composições farmacêuticas, e, uso dos compostos
DE602004019405D1 (de) Pharmazeutische zubereitungen
EP1229025A4 (en) NEW QUINAZOLINE DERIVATIVES
BR9912218A (pt) Compostos obtidos de espécies de sálvia possuindo atividade antivirótica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1914 DE 11/09/2007 POR TER SIDO INDEVIDO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL A61K47/48, A61K 47/32, A61K 47/38, A61K 31/18, A61K 31/216, A61K 31/404, A61K 31/515, A61K 31/5517, C07D 239/60, C07D 403/14, C07D 243/06

Ipc: A61K 47/48 (2008.04), A61K 47/32 (2008.04), A61K 4

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O E ART. 13 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/14 (2006.01), A61K 47/56 (2017.0